668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668
Authors:
Mark N. Stein
Oscar Goodman
Tanya B. Dorff
Vivek Narayan
Jose Avitia
Rana R. McKay
Luke T. Nordquist
Matthew B. Rettig
Michael T. Schweizer
Roby Thomas
Michael E. Silverman
Li Yao
Raphael Clynes
Jolene Shorr
Affiliated Authors:
Mark N. Stein
Columbia Affiliation:
Subjects:
Cancer Immunotherapy (OpenAlex Topic)
Advancements in Prostate Cancer Research (OpenAlex Topic)
Development and Applications of Radiopharmaceuticals (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-sitc2022.0668
DOI:
10.1136/jitc-2022-sitc2022.0668
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: